ePrints

Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes

Lookup NU author(s): Dr Niraj Ahuja

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Catatonia is a common neuropsychiatric syndrome which may arise from GABA-A hypoactivity, dopamine (D2) hypoactivity, and possibly glu-tamate NMDA hyperactivity. Amantadine and memantine have been reported as effective treatments for catatonia in selected cases, and probably mediate the presence of catatonic signs and symptoms through complex pathways involving glutamate antagonism. The authors identified 25 cases of catatonia treated with either agent. This article provides indirect evidence that glutamate antagonists may improve catatonic signs in some patients who fail to respond to established treatment, including lorazepam or electroconvulsive therapy. Further study of glutamate antagonists in the treatment of catatonia is needed. Copyright © 2007 American Psychiatric Publishing, Inc.

Publication metadata

Author(s): Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus MF, Spiegel DR, Franco KN, Pozuelo L, Munoz C

Publication type: Article

Publication status: Published

Journal: Journal of Neuropsychiatry and Clinical Neurosciences

Year: 2007

Volume: 19

Issue: 4

Pages: 406-412

ISSN (print): 0895-0172

ISSN (electronic): 1545-7222

Publisher: American Psychiatric Publishing, Inc.

URL: http://dx.doi.org/10.1176/appi.neuropsych.19.4.406

DOI: 10.1176/appi.neuropsych.19.4.406

PubMed id: 18070843

Altmetrics

Share